Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01351376 · ClinicalTrials.gov registry record · NA

LLLT Combined With CDT in Breast Cancer-Related Lymphedema

A NA study, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
21
Enrollment target

NCT01351376: Completed NA study, sponsored by NYU Langone Health.

NCT01351376 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01351376, a NA study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target

Study Summary

This study aims to explore the effects of Low Level Laser Therapy (LLLT) on breast cancer-related lymphedema when utilized in conjunction with Complex Decongestive Therapy (CDT) when compared to CDT treatment alone. The investigators hypothesize that the addition of LLLT to CDT will result in statistically significant improvements and greater long-term benefits as measured by changes in arm volume and quality of life when compared to the benefits of CDT alone for the treatment of breast cancer-related lymphedema.

Interventions

  • DEVICE Low Level Laser Therapy
  • DEVICE Low Level Laser

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2011-05
Est. Completion 2017-07
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT01351376 record still lists

NCT01351376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Low Level Laser Therapy is the first listed.

NCT01351376 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01351376 about?

NCT01351376 is a clinical study titled "LLLT Combined With CDT in Breast Cancer-Related Lymphedema". This study aims to explore the effects of Low Level Laser Therapy (LLLT) on breast cancer-related lymphedema when utilized in conjunction with Complex Decongestive Therapy (CDT) when compared to CDT treatment alone. The investigators hypothesize that the addition of LLLT to CDT will result in statis...

What is the current status of trial NCT01351376?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2011-05. Estimated completion is 2017-07.

What interventions are being tested in trial NCT01351376?

The interventions under investigation include: Low Level Laser Therapy (DEVICE), Low Level Laser (DEVICE).

Who is sponsoring clinical trial NCT01351376?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01351376's enrollment target sits among peer trials

21 1762nd of 2000 higher than 233 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01351376, the US trial registry maintained by the National Library of Medicine. NCT01351376 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.